AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. (“Mati”) announced today that it has been granted U.S. Patent No. 9,011,361 entitled “Lacrimal Implant Detection” and European Union Patent No. EP2614844 entitled “Drug Cores for Sustained Release of Therapeutic Agents.” These patents provide coverage for important elements of Mati’s novel punctal plug delivery system (“PPDS”) for treatment of ocular indications including certain features for detecting the implants in the puncta and in the
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/c33pgm/global_and) has announced the addition of the “Global and Chinese Soft Hydrophilic Contact Lens Industry, 2010-2020 Market Research Report” report to their…
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015.
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company that has developed and is currently marketing the Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia, announced today the appointment of John Strobel as Vice President of Sales. Mr. Strobel will be responsible for Presbia’s international sales expansion of the Presbia Flexivue Microlens™. “John’s extensive experience in the ophthalmology industry as well as his demonstrated tra
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation announced that it will release its first quarter 2015 financial results after close of market on Monday, May 11, 2015.
TAMPA, Fla.–(BUSINESS WIRE)–Retina Associates of Tampa pilot study suggests that single Ranibizumab injection with peripheral laser therapy can treat DME associated with peripheral retina nonperfusion.
DENVER–(BUSINESS WIRE)–Allegro Ophthalmics announced that it has begun enrolling patients in a Phase 2 clinical trial that will evaluate Luminate® in inducing PVD in patients with non-proliferative diabetic retinopathy.
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that it will host a conference call on Thursday, May 7, 2015 at 4:30 p.m. EDT, during which it will provide a corporate update for the first quarter of 2015. Interested parties may access the call live by dialing (800) 753-0487 (US) or (913) 312-0713 (international) and using conference ID 3671771. A live audio webcast of t
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today announced that preclinical data demonstrating that Cell Cure’s product candidate, OpRegen®, preserved vision and retinal structure when transplanted into the leading animal model of retinal disease, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting taking place May 3-7, 2015, in Denver, Colorado. OpRe
NEW YORK–(BUSINESS WIRE)–Ophthotech announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Deutsche Bank 40th Annual Health Care May 7, 2015 at 10:00 a.m. ET.
ALPHARETTA, Ga. & EMERYVILLE, Calif.–(BUSINESS WIRE)–Clearside Biomedical, which develops drug therapies to treat eye diseases, and Santen Inc., a Santen Pharmaceuticals Co. subsidiary, will expand their research collaboration to include glaucoma.
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO: 4589) (“Acucela” or the “Company”), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, today announced that shareholders have elected four new members to the Company’s Board of Directors (the “Board”) at today’s special meeting of the Company’s shareholders (the “Special Meeting”). At the Special Meeting,
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced new data will be presented on the company’s sustained release technology at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting at the Colorado Convention Center in Denver, Colorado, from May 3-7, 2015. The data presented will focus on the
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida Announces May 8 for Third Quarter Fiscal Year 2015 Financial Results and Release Date and Conference Call Information
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to restore functional vision to blind patients, today announced two senior management appointments in commercialization and manufacturing. As discussed on its fourth quarter 2014 conference call, the Company will be making several key hires as it continues the transition from an R&D focused organization
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced that a study has been published that includes top-line, positive results in Asian patients who were treated with Ocata’s proprietary RPE cells, manufactured using its DeltaCell™ Technology. These new data support previously reported positive long-term safety and signs of visual improvement, as presented in The Lancet of October 1
ALISO VIEJO, Calif.–(BUSINESS WIRE)–AqueSys XEN Gel Stent data supporting safety and effectiveness presented at the recent American Society of Cataract & Refractive Surgery annual meeting.
WEST ORANGE, N.J.–(BUSINESS WIRE)–ZRG Partners, Inc. has announced the findings for its first quarter Global Life Sciences Hiring Index from 2015.
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, which develops drug therapies to treat eye diseases, will present its Phase 1/2 clinical trial results May 5 at the Association for Research and Vision in Ophthalmology meeting.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics Reports First Quarter 2015 Financial Results